You are now leaving the ViiV Healthcare website and being re-directed to an external website
Explore ViiV Healthcare
Read the report, available now inEnglish and Spanish
As the only company solely focused on HIV, we go beyond developing new medicines. We take a holistic approach to HIV by developing and supporting sustainable community programs — with and for the HIV community.
ViiV Healthcare has a long-standing commitment to activities that deliver education, treatment and prevention and access to care through on-the-ground programs.
The voice of the HIV community informs everything we do to improve the lives and health outcomes of all people living with HIV.
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra-long-acting” medicines for HIV
Read all news
We must stand together to reduce disparities in communities disproportionately impacted by HIV, with the goal of leaving no person living with HIV behind.
Read how to report a side effect.
Website images are not intended to imply that the models pictured have HIV.
©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare US, Five Moore Drive, Research Triangle Park, North Carolina USA, 27709-3398.
Connect with us